Companies

Medgenics Inc

Overview

Israel-based Medgenics Inc is a biopharmaceutical company, which has developed a technology that could replace regular injections as a treatment for various ailments. This is described by the company as a biological Biopump. A skin biopsy is taken from a patient and processed for two weeks in order for it to produce the required protein. It is then put back in the body, under the skin. This can provide a sustained dose of the required treatment which can last for weeks or months. The first product is called EPODURE, because it produces EPO (erythro-protein) to treat anaemia. The second product in development is INFRADURE, which is designed for the production and sustained delivery of interferon-alpha for the treatment of hepatitis C. Medgenics joined Aim on 4 December 2007 when it raised £3.276m at 10p a share.

Sector: Health

News blog

• Medgenics Inc Posted: 16/08/2010
• Medgenics Inc Posted: 26/05/2010
• Medgenics Inc Posted: 05/05/2010
• Medgenics Inc Posted: 27/10/2009
• Medgenics Inc Posted: 31/08/2009
• Medgenics Inc Posted: 20/08/2009
• Medgenics Inc Posted: 27/03/2009
• Medgenics Inc Posted: 03/02/2009
• Medgenics Inc Posted: 11/01/2009

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period